Literature DB >> 27825770

Estimating Longitudinal Risks and Benefits From Cardiovascular Preventive Therapies Among Medicare Patients: The Million Hearts Longitudinal ASCVD Risk Assessment Tool: A Special Report From the American Heart Association and American College of Cardiology.

Donald M Lloyd-Jones, Mark D Huffman, Kunal N Karmali, Darshak M Sanghavi, Janet S Wright, Colleen Pelser, Martha Gulati, Frederick A Masoudi, David C Goff.   

Abstract

The Million Hearts Initiative has a goal of preventing 1 million heart attacks and strokes-the leading causes of mortality-through several public health and healthcare strategies by 2017. The American Heart Association and American College of Cardiology support the program. The Cardiovascular Risk Reduction Model was developed by Million Hearts and the Center for Medicare & Medicaid Services as a strategy to assess a value-based payment approach toward reduction in 10-year predicted risk of atherosclerotic cardiovascular disease (ASCVD) by implementing cardiovascular preventive strategies to manage the "ABCS" (aspirin therapy in appropriate patients, blood pressure control, cholesterol management, and smoking cessation). The purpose of this special report is to describe the development and intended use of the Million Hearts Longitudinal ASCVD Risk Assessment Tool. The Million Hearts Tool reinforces and builds on the "2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk" by allowing clinicians to estimate baseline and updated 10-year ASCVD risk estimates for primary prevention patients adhering to the appropriate ABCS over time, alone or in combination. The tool provides updated risk estimates based on evidence from high-quality systematic reviews and meta-analyses of the ABCS therapies. This novel approach to personalized estimation of benefits from risk-reducing therapies in primary prevention may help target therapies to those in whom they will provide the greatest benefit, and serves as the basis for a Center for Medicare & Medicaid Services program designed to evaluate the Million Hearts Cardiovascular Risk Reduction Model.
Copyright © 2017 American Heart Association, Inc., and the American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AHA Scientific Statements; cardiovascular diseases; morbidity; mortality; myocardial infarction; population; prevention; stroke

Mesh:

Year:  2016        PMID: 27825770      PMCID: PMC5370170          DOI: 10.1016/j.jacc.2016.10.018

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  75 in total

Review 1.  Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease: An Overview of Systematic Reviews.

Authors:  Kunal N Karmali; Donald M Lloyd-Jones; Mark A Berendsen; David C Goff; Darshak M Sanghavi; Nina C Brown; Liliya Korenovska; Mark D Huffman
Journal:  JAMA Cardiol       Date:  2016-06-01       Impact factor: 14.676

2.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.

Authors:  Gordon H Guyatt; Andrew D Oxman; Gunn E Vist; Regina Kunz; Yngve Falck-Ytter; Pablo Alonso-Coello; Holger J Schünemann
Journal:  BMJ       Date:  2008-04-26

3.  Value of primordial and primary prevention for cardiovascular disease: a policy statement from the American Heart Association.

Authors:  William S Weintraub; Stephen R Daniels; Lora E Burke; Barry A Franklin; David C Goff; Laura L Hayman; Donald Lloyd-Jones; Dilip K Pandey; Eduardo J Sanchez; Andrea Parsons Schram; Laurie P Whitsel
Journal:  Circulation       Date:  2011-07-25       Impact factor: 29.690

4.  Primary prevention of cardiovascular disease with a Mediterranean diet.

Authors:  Ramón Estruch; Emilio Ros; Jordi Salas-Salvadó; Maria-Isabel Covas; Dolores Corella; Fernando Arós; Enrique Gómez-Gracia; Valentina Ruiz-Gutiérrez; Miquel Fiol; José Lapetra; Rosa Maria Lamuela-Raventos; Lluís Serra-Majem; Xavier Pintó; Josep Basora; Miguel Angel Muñoz; José V Sorlí; José Alfredo Martínez; Miguel Angel Martínez-González
Journal:  N Engl J Med       Date:  2013-02-25       Impact factor: 91.245

5.  Paying for Prevention: A Novel Test of Medicare Value-Based Payment for Cardiovascular Risk Reduction.

Authors:  Darshak M Sanghavi; Patrick H Conway
Journal:  JAMA       Date:  2015-07-14       Impact factor: 56.272

Review 6.  2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents.

Authors:  Donald M Lloyd-Jones; Pamela B Morris; Christie M Ballantyne; Kim K Birtcher; David D Daly; Sondra M DePalma; Margo B Minissian; Carl E Orringer; Sidney C Smith
Journal:  J Am Coll Cardiol       Date:  2016-04-01       Impact factor: 24.094

7.  Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria.

Authors:  Folkert W Asselbergs; Gilles F H Diercks; Hans L Hillege; Ad J van Boven; Wilbert M T Janssen; Adriaan A Voors; Dick de Zeeuw; Paul E de Jong; Dirk J van Veldhuisen; Wiek H van Gilst
Journal:  Circulation       Date:  2004-10-18       Impact factor: 29.690

Review 8.  Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force.

Authors:  Tracy Wolff; Therese Miller; Stephen Ko
Journal:  Ann Intern Med       Date:  2009-03-17       Impact factor: 25.391

9.  Prevalence of hypertension and controlled hypertension - United States, 2007-2010.

Authors:  Cathleen D Gillespie; Kimberly A Hurvitz
Journal:  MMWR Suppl       Date:  2013-11-22

10.  Risk score overestimation: the impact of individual cardiovascular risk factors and preventive therapies on the performance of the American Heart Association-American College of Cardiology-Atherosclerotic Cardiovascular Disease risk score in a modern multi-ethnic cohort.

Authors:  Andrew Paul DeFilippis; Rebekah Young; John W McEvoy; Erin D Michos; Veit Sandfort; Richard A Kronmal; Robyn L McClelland; Michael J Blaha
Journal:  Eur Heart J       Date:  2017-02-21       Impact factor: 29.983

View more
  27 in total

1.  Medicare, Metrics and Trust in the Future.

Authors:  Julie Babyar
Journal:  J Med Syst       Date:  2018-07-09       Impact factor: 4.460

2.  A controlled trial of dissemination and implementation of a cardiovascular risk reduction strategy in small primary care practices.

Authors:  Samuel Cykert; Thomas C Keyserling; Michael Pignone; Darren DeWalt; Bryan J Weiner; Justin G Trogdon; Thomas Wroth; Jacqueline Halladay; Monique Mackey; Jason Fine; Jung In Kim; Crystal Cene
Journal:  Health Serv Res       Date:  2020-10-13       Impact factor: 3.402

3.  Target blood pressure and cardiovascular risk.

Authors:  Céline Dreyfuss-Tubiana; Philippe Sosner; Jacques Blacher
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

Review 4.  ImPlementation REsearCh to DEvelop Interventions for People Living with HIV (the PRECluDE consortium): Combatting chronic disease comorbidities in HIV populations through implementation research.

Authors:  Joyonna Carrie Gamble-George; Christopher T Longenecker; Allison R Webel; David H Au; Arleen F Brown; Hayden Bosworth; Kristina Crothers; William E Cunningham; Kevin A Fiscella; Alison B Hamilton; Christian D Helfrich; Joseph A Ladapo; Amneris Luque; Jonathan N Tobin; Gail E Wyatt
Journal:  Prog Cardiovasc Dis       Date:  2020-03-19       Impact factor: 8.194

5.  Association of Cumulative Systolic Blood Pressure With Long-Term Risk of Cardiovascular Disease and Healthy Longevity: Findings From the Lifetime Risk Pooling Project Cohorts.

Authors:  Orna Reges; Hongyan Ning; John T Wilkins; Colin O Wu; Xin Tian; Michael J Domanski; Donald M Lloyd-Jones; Norrina B Allen
Journal:  Hypertension       Date:  2020-12-21       Impact factor: 10.190

6.  Prediction of individualized lifetime benefit from cholesterol lowering, blood pressure lowering, antithrombotic therapy, and smoking cessation in apparently healthy people.

Authors:  Nicole E M Jaspers; Michael J Blaha; Kunihiro Matsushita; Yvonne T van der Schouw; Nicholas J Wareham; Kay-Tee Khaw; Marie H Geisel; Nils Lehmann; Raimund Erbel; Karl-Heinz Jöckel; Yolanda van der Graaf; W M Monique Verschuren; Jolanda M A Boer; Vijay Nambi; Frank L J Visseren; Jannick A N Dorresteijn
Journal:  Eur Heart J       Date:  2020-03-14       Impact factor: 35.855

Review 7.  A Review of Chronic Comorbidities in Adults Living With HIV: State of the Science.

Authors:  Allison R Webel; Julie Schexnayder; Patricia A Cioe; Julie A Zuñiga
Journal:  J Assoc Nurses AIDS Care       Date:  2021 May-Jun 01       Impact factor: 1.809

8.  Reducing Cardiovascular Risk in the Medicare Million Hearts Risk Reduction Model: Insights From the National Cardiovascular Data Registry PINNACLE Registry.

Authors:  William B Borden; Jingyan Wang; Philip Jones; Yuanyuan Tang; Johanna Contreras; Stacie L Daugherty; Nihar R Desai; Salim S Virani; Jason H Wasfy; Thomas M Maddox
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2022-03-11

9.  Communicating personalised statin therapy-effects as 10-year CVD-risk or CVD-free life-expectancy: does it improve decisional conflict? Three-armed, blinded, randomised controlled trial.

Authors:  Nicole E M Jaspers; Frank L J Visseren; Yolanda van der Graaf; Yvo M Smulders; Olga C Damman; Corline Brouwers; Guy E H M Rutten; Jannick A N Dorresteijn
Journal:  BMJ Open       Date:  2021-07-16       Impact factor: 2.692

10.  SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions.

Authors: 
Journal:  Eur Heart J       Date:  2021-07-01       Impact factor: 35.855

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.